Following the passage of continuing resolutions (CR) by the US Senate and the House of Representatives this week, lab test reimbursement cuts and price reporting requirements called for under the Protecting Access to Medicare Act (PAMA) are likely to be delayed one year.

Colorectal cancer is a significant health concern in China, with high incidence and mortality rates. Research indicates that screening and early diagnosis, especially for high-risk groups, can significantly improve early detection and reduce mortality.

According to recent monitoring data, China recorded 1,060,600 new cases of lung cancer in 2022, accounting for 22% of all malignant tumors.

By 2030, a diabetes prevention and treatment system will enable over 60% of residents aged 18 and above to be aware of the disease. By then, the coverage rate of standardized management services for type 2 diabetes patients at the primary level will exceed 70%, according to the documents released by multiple departments including the National Health Commission (NHC).

On 30 July, Information Office of Shanghai Municipality held a press briefing, introducing the details of the “Several Opinions on Supporting the Innovation and Development of the Entire Biomedicine Industry Chain.”

Since the end of 2019, biochemical diagnosis companies have faced severe challenges due to the impact of the political and economic environment.

In 2019, the State Council successively promulgated three policy documents closely related to the biochemical analysis instruments and reagents, which laid an important policy foundation for the development of biochemical analysis instruments and reagents.

China's respiratory testing market shows significant growth potential, driven by increasing demand, technological advancements, supportive policies, and a growing market size.

The US Food and Drug Administration released on Monday its final rule to regulate laboratory-developed tests (LDTs).

The House Select Committee on the Strategic Competition between the United States and the Chinese Communist Party said on Thursday that it has introduced a new bill to ban the use of federal funding on "foreign adversary biotech companies," including China's BGI Group.